trial

Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism

NCTId NCT00463346
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 23 (actual)
Sponsored by Yale University
Primary completion 2015-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
23 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2006-09
Primary completion
2015-07
Eligibility
ALL · 21 Years · 65 Years

Interventions & indications

Drugs
Acamprosate

Sponsors

Yale UniversityLead Sponsor
Forest LaboratoriesCollaborator

Investigators

1
Ismene L Petrakis, MDPrincipal Investigator

Sites

1 total
West Haven, United States

Linked catalysts

1
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholis — primary completion2015-07

Facts & assertions

4 sourced
Enrollment
23
Phase
PHASE3
Primary Completion Date
2015-07
Status
COMPLETED
relationships
The graph out of here
drug
Acamprosate
drug
lead_sponsor
Yale University
company
collaborator
Forest Laboratories
company
indication
Schizophrenia
indication
Schizophrenia
indication
Alcoholism
indication
investigator
Ismene L Petrakis, MD
person